SGLT2 Toys: A Cost-Effective Analysis
According In 2012, 29.1 million people in the United States, approximately 9.3% of the population were diagnosed with diabetes mellitus, of whom 90% to 95% of adults had type 2 diabetes[1]. Although drug costs are increasing, the greatest component of the economic burden of T2DM is the treatment of diabetic complications, which can be reduced with effective management of the disease[2]. The SGLT2 inhibitors are a novel anti-diabetic agents with similar glycemic efficacy to other oral anti-hyperglycemic agents and low risk for hypoglycemia. There is a lack of published literature evaluating the economic benefits of SGLT2 inhibitors such as dapagliflozin. This cost-effectiveness analysis evaluates the long-term economic consequences of SGLT2
inhibitors versus DPP-4 inhibitors add-on to metformin as second-line therapy in T2DM. This literature review relevant articles were searched in PubMed, EMBASE. Inclusion criteria include Papers published between January 2012 and February 2016, and published in English. Key words are Pharmacoeconomic, Cost-effectiveness analysis, Cost-utility analysis, Cost-benefit analysis and Canagliflozin, Dapagliflozin, Empagliflozin, SGLT. The PubMed search identified 8 articles, whereas the EMBASE search identified 27 articles. A total of 5 articles were included for this literature review. The clinical input in major source of effectiveness data was from medical literature include phase Ⅲ clinical trial. The main assessment metric was HbA1c reduction, weight reduction, systolic blood pressure reduction, Costs, life years (LYs) gained, quality-adjusted life-years (QALYs) and the incremental cost-effectiveness ratio (ICER) for SGLT2 inhibitors compared with DPP-4 inhibitors therapy. This literature review summarizes current evidence from Pharmacoeconomic study evaluating the SGLT2 inhibitors was cost-effectiveness, include of dapagliflozin, canagliflozin[2-6]. The economic evaluation was conducted from the perspective of the modeling that offer another choice on cost-effectiveness, but we don’t know how about this in Taiwan. Future clinical and cost inputs required for the simulation will be obtained, where appropriate, from the National Health Insurance Research Database.
inhibitors versus DPP-4 inhibitors add-on to metformin as second-line therapy in T2DM. This literature review relevant articles were searched in PubMed, EMBASE. Inclusion criteria include Papers published between January 2012 and February 2016, and published in English. Key words are Pharmacoeconomic, Cost-effectiveness analysis, Cost-utility analysis, Cost-benefit analysis and Canagliflozin, Dapagliflozin, Empagliflozin, SGLT. The PubMed search identified 8 articles, whereas the EMBASE search identified 27 articles. A total of 5 articles were included for this literature review. The clinical input in major source of effectiveness data was from medical literature include phase Ⅲ clinical trial. The main assessment metric was HbA1c reduction, weight reduction, systolic blood pressure reduction, Costs, life years (LYs) gained, quality-adjusted life-years (QALYs) and the incremental cost-effectiveness ratio (ICER) for SGLT2 inhibitors compared with DPP-4 inhibitors therapy. This literature review summarizes current evidence from Pharmacoeconomic study evaluating the SGLT2 inhibitors was cost-effectiveness, include of dapagliflozin, canagliflozin[2-6]. The economic evaluation was conducted from the perspective of the modeling that offer another choice on cost-effectiveness, but we don’t know how about this in Taiwan. Future clinical and cost inputs required for the simulation will be obtained, where appropriate, from the National Health Insurance Research Database.